COMP <GO>
ETON vs PAHC // EV/EBITDA & P/E VALUATION
Eton Pharmaceuticals Inc. (NASDAQ) VS. Phibro Animal Health Corporation (Class A) (NASDAQ) • 15-METRIC TALLY: ETON 3
— PAHC 8
■ METRIC PARITY
LAST: $53.67 (+3.61%) • MKT CAP: $1.53B
valuation
—
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. PAHC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ETON | PAHC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 30.90% | +22.60 | ETON | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.90% | 9.90% | -10.80 | PAHC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 19.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.66% | 5.08% | -4.42 | PAHC | /fcf-yield <GO> |
| Operating Margin | -1.10% | 8.50% | -9.60 | PAHC | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 3.70% | -9.50 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | 104.90% | 27.40% | +77.50 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.23% | -1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.37 | 2.87 | +10.50 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 56.9 | -9.01 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 27.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $1.58B | -$43.7M | PAHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ETON REV | PAHC REV | ETON GROSS % | PAHC GROSS % | ETON FCF | PAHC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.0M | $1.30B | 53.5% | 30.9% | $10.2M | $80.1M |
| FY 2024 | $39.0M | $1.02B | 60.0% | 30.8% | $943.0K | $87.6M |
| FY 2023 | $31.6M | $977.9M | — | — | $6.8M | $13.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
PAHC // BETA —